Adjuvants for vaccines against respiratory syncytial virus
US5723130A · kind A · utility
49Cited by
2References
6Claims
0Family size
Inventors
Key dates
| Filing date | Sep 16, 1996 |
| Grant date | Mar 3, 1998 |
| Priority date | — |
| Expiry date | Sep 16, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55577
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vaccine formulations and therapeutic methods therefor containing respiratory syncytial viral proteins or immunological fragment and an adjuvant selected from the group consisting of QS-21 3-deacylated monophosphoryl lipid A, monopohosphoryl lipid A and combination are described herein. Presence of the adjuvant(s) significantly increases the humoral and cell-mediated immunogenicity of the RSV proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.